Abbreviations: ANOVA, analysis of variance; Adcy4, adenylate cyclase 4; Atp1b3, beta 3 polypeptide; BMMs, bone marrow macrophages; BMPs, bone morphogenetic proteins; BV, bone volume ; SLE, systemic lupus erythematosus; BV/TV, Bone volume/total volume; Capn1, calpain 1; CatK, Cathepsin K; cDNA, complementary deoxyribonucleic acid; DAB, diaminobenzidine; EDTA, Ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; Grin2a, glutamate receptor, ionotropic, NMDA2A (epsilon 1); GH, growth hormone; H1F1α, hypoxia inducible factor 1 α; IGF1, insulin-like growth factor 1; Itgb1, integrin beta 1; KEGG, Kyoto Encyclopedia of Genes and Genomes; LC-MS, liquid chromatography and mass spectrometry; M-CSF, macrophage cloning stimulating factor; microCT, micro-computed tomography; MAR, mineral apposition rate; α-MEM, Minimum Essential Medium Eagle -Alpha Modification; Nfatc1, nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1(Nfatc1); NTX-1, N-terminal telopeptides of type-1 collagen; OB, osteoblasts; OC, osteoclasts; OPG, osteoprotegerin; pAKT, protein kinase B; Pik3r2, phosphatidylinositol 3-kinase, regulatory subunit, and polypeptide 2 (p85 beta); PBS, phosphate buffer; PCNA, proliferation cell nuclear antigen; Ppp1r12b, protein phosphatase 1, regulatory (inhibitor) subunit 12B; pSMAD5, phosphorylated mothers against decapentaplegic homolog 5; p38MAPK, P38 mitogen-activated protein kinases; P1NP, Cross-linked C-telopeptide of type 1 collagen; PXN, paxillin; qPCR, quantitative polymerase chain reaction; RANKL, Receptor activator of nuclear factor kappa-Β ligand; Rac2, RAS-related C3 botulinum substrate 2; RNA, ribonucleic acid; SD, standard deviation; Sos1, son of sevenless homolog 1; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; TRAP, tartrate-resistant acid phosphatase; Ult Load, ultimate load force.
Correspondence
AbstractThe MRL/MpJ mice have demonstrated an enhanced tissue regeneration capacity for various tissues. In the present study, we systematically characterized bone microarchitecture and found that MRL/MpJ mice exhibit higher bone microarchitecture and strength compared to both C57BL/10J and C57BL/6J WT mice at 2, 4, and 10 months of age. The higher bone mass in MRL/MpJ mice was correlated to increased osteoblasts, decreased osteoclasts, higher cell proliferation, and bone formation, and enhanced pSMAD5 signaling earlier during postnatal development (2-month old) in the spine trabecular bone, and lower bone resorption rate at later age. Furthermore, these mice exhibit accelerated fracture healing via enhanced pSMAD5, pAKT and p-P38MAPK pathways compared to control groups. Moreover, MRL/MpJ mice demonstrated resistance to ovariectomy-induced bone loss as evidenced by maintaining higher bone volume/tissue volume (BV/TV) and lower percentage of bone loss later after ovariectomy. The consistently higher serum IGF1 level and lower RANKL 790 | SUN et al.